Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled, Pilot Study of the Combination of Valacyclovir + Celecoxib (IMC-2) for the Treatment of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib+valacyclovir-Virios Therapeutics (Primary)
Indications Fatigue; Post acute COVID 19 syndrome
Focus Proof of concept; Therapeutic Use
Acronyms BHC Study 202; PASC
Sponsors Dogwood Therapeutics

Most Recent Events

18 Nov 2024 Results presented in a Dogwood Therapeutics media release.
18 Nov 2024 Status changed from active, no longer recruiting to completed, according to Dogwood Therapeutics media release.
30 Oct 2024 According to Virios Therapeutics media release, Virios Therapeutics has changed its name to Dogwood Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com